Hypertension in type 2 diabetes mellitus

Insulin

Volumn 1, Issue 1, 2006, Pages 22-37

  Hayden, Melvin R ^a   Sowers, James R ^a  

^a University of Missouri   (United States)

Author keywords

angiotensin converting enzyme (ACE) inhibitor; angiotensin receptor blocker (ARB); hyperamylinemia; hyperglycemia or glucotoxicity; hyperinsulinemia; hyperproinsulinemia; insulin resistance; renin angiotensin aldosterone system (RAAS) blockade

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALDOSTERONE ANTAGONIST; ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARVEDILOL; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; HYDROCHLOROTHIAZIDE; INSULIN; LISINOPRIL; LOSARTAN; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; UNINDEXED DRUG; VERAPAMIL;

ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; COUGHING; DRUG MEGADOSE; DRUG POTENTIATION; ENDOTHELIAL DYSFUNCTION; ENVIRONMENTAL FACTOR; FATIGUE; GYNECOMASTIA; HEREDITY; HORMONE METABOLISM; HUMAN; HYPERKALEMIA; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DISEASE; MEDLINE; METABOLIC DISORDER; MICROALBUMINURIA; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE;

EID: 33646070518     PISSN: 15570843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1557-0843(06)80005-9     Document Type: Article

References (79)

1. Kylin E. Studien ueber das Hypertonie-Hyperglykamie Hyperurikamiesyndrom. Zentralblatt fuer Innere Medizin 44 (1923) 105-127
2. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
3. Reaven G.M., Lithell H., and Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334 (1996) 374-381
4. Vague J. Sexual differentiation, a factor affecting the forms of obesity. Presse Méd 30 (1947) 339-340
5. Sowers J.R., Sowers P.S., and Peuler J.D. Role of insulin resistance and hyperinsulinemia in development of hypertension and atherosclerosis. J Lab Clin Med 123 (1994) 647-652
6. Stern M.P. Diabetes and cardiovascular disease. The "common soil" hypothesis. Diabetes 44 (1995) 369-374
7. McFarlane S.I., Banerji M., and Sowers J.R. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 86 (2001) 713-718
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
9. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26 Suppl 1 (2003) 55-520
10. American Diabetes Association National Diabetes Fact Sheet. Available at: http://www.diabetes.org/diabetes-statistics/national-diabetes-fact-sheet .jsp. Accessed July 31, 2005.
11. Hayden M.R. Islet amyloid, metabolic syndrome, and the natural progressive history of type 2 diabetes mellitus. JOP 3 (2002) 126-138
12. Hayden M.R., and McGowan B.S. Understanding the links between insulin resistance, diabetes, and cardiovascular risk. Practical Diabetol 24 (2005) 6-14
13. Dandona P., Aljada A., Dhindsa S., and Garg R. Insulin as an anti-inflammatory and antiatherosclerotic hormone. Clin Cornerstone Suppl 4 (2003) S13-S20
14. Hayden M.R. Global risk reduction of reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy. Med Hypotheses Res 1 (2004) 171-185
15. Nickenig G., Roling J., Strehlow K., et al. Insulin induces upregulation of vascular AT1 receptor gene expression by posttranscriptional mechanisms. Circulation 98 (1998) 2453-2460
16. Westermark P., Wernstedt C., O'Brien T.D., et al. Islet amyloid in type 2 human diabetes mellitus and adult diabetic cats contains a novel putative polypeptide hormone. Am J Pathol 127 (1987) 414-417
17. Cooper G.J., Willis A.C., Clark A., et al. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84 (1987) 8628-8632
18. Hayden M.R., Tyagi S.C., Kerklo M.M., and Nicolls M.R. Type 2 diabetes mellitus as a conformational disease. JOP 6 (2005) 287-302
19. Butler A.E., Janson J., Soeller W.C., and Butler P.C. Increased betacell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: Evidence for role of islet amyloid formation rather than direct action of amyloid. Diabetes 52 (2003) 2304-2314
20. Hayden M.R., and Tyagi S.C. "A" is for amylin and amyloid in type 2 diabetes mellitus. JOP 2 (2001) 124-139
21. Hayden M.R., and Tyagi S.C. Islet redox stress: The manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. JOP 3 (2002) 86-108
22. Reda T.K., Geliebter A., and Pi-Sunyer F.X. Amylin, food intake, and obesity. Obes Res 10 (2002) 1087-1091
23. Kailasam M.T., Parmer R.J., Tyrell E.A., et al. Circulating amylin in human essential hypertension: Heritability and early increase in individuals at genetic risk. J Hypertens 18 (2000) 1611-1620
24. Hollander P., Maggs D.G., Ruggles J.A., et al. Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients. Obes Res 12 (2004) 661-668
25. Schmitz O., Brock B., and Rungby J. Amylin agonists: A novel approach in the treatment of diabetes. Diabetes 53 Suppl 3 (2004) 5233-5238
26. Haynes W.G. Role of leptin in obesity-related hypertension. Exp Physiol 90 (2005) 683-688
27. Hayden M.R., Sowers J.R., and Tyagi S.C. The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: The matrix preloaded. Cardiovasc Diabetol 4 (2005) 9
28. Hayden M.R., and Tyagi S.C. Intimal redox stress: Accelerated atherosclerosis in metabolic syndrome and type 2 diabetes mellitus. Atheroscleropathy. Cardiovasc Diabetol 1 (2002) 3
29. McGarry J. Banting lecture 2001: Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51 (2002) 7-18
30. Ritz E., and Dikow R. Angiotensin receptor antagonists in patients with nephropathy due to type 2 diabetes. Ann Med 34 (2002) 507-513
31. Sowers J.R. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol 286 (2004) H1597-H1602
32. Cheng Z.J., Vaskonen T., Tikkanen I., et al. Endothelial dysfunction and salt-sensitive hypertension in spontaneously diabetic Goto-Kakizaki rats. Hypertension 37 (2001) 433-439
33. Standley P.R., Rose K.A., and Sowers J.R. Increased basal arterial smooth muscle glucose transport in the Zucker rat. Am J Hypertens 8 (1995) 48-52
34. Bakris G.L., Williams M., Dworkin L., et al., National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: A consensus approach. Am J Kidney Dis 36 (2000) 646-661
35. Sowers J.R. Diabetic nephropathy and concomitant hypertension: A review of recent ADA recommendations. Am J Clin Proc 3 (2002) 27-33
36. American Diabetes Association. Treatment of hypertension in adults with diabetes: Clinical practice recommendations. Diabetes Care 25 Suppl 1 (2002) 571-579
37. Chobanian A.V., Bakris G.L., Black H.R., et al., Joint National Committee on Prevention, Detection Evaluation, and Treatment of High Blood Pressure, and the National Heart, Lung, and Blood Institute: National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
38. Rankins J., Sampson W., Brown B., and Jenkins-Salley T. Dietary Approaches to Stop Hypertension (DASH) intervention reduces blood pressure among hypertensive African American patients in a neighborhood health care center. J Nutr Educ Behav 37 (2005) 259-264
39. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 47 (1995) 1703-1720
40. [published correction appears in BMJ. 1999;318:29]. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-717
41. Whaley-Connell A., and Sowers J.R. Hypertension management in type 2 diabetes mellitus: Recommendations of the Joint National Committee VII. Endocrinol Metab Clin North Am 34 (2005) 63-75
42. Sowers J.R. Recommendations for special populations: Diabetes mellitus and the metabolic syndrome. Am J Hypertens 16 (2003) 41S-45S
43. Janke J., Engeli S., Gorzelniak K., et al. Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 51 (2002) 1699-1707
44. Bakris G.L., and Weir M.R. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: Is this a cause for concern?. Arch Intern Med 160 (2000) 685-693
45. Brenner B.M., Cooper M.E., de Zeeuw D., et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
46. Lewis E.L., Hunsicker L.G., Clarke W.R., and Collaborative Study Group^. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
47. Viberti G.C., Wheeldon N.M., and MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: A blood pressureindependent effect. Circulation 106 (2002) 672-678
48. [published correction appears in JAMA. 2003;290:197]. Chobanian A.V., Bakris G.L., Black H.R., et al., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; the INC 7 report. JAMA 289 (2003) 2560-2572
49. Hayden M.R., Whaley-Connell A., and Sowers J.R. Renal redox stress and remodeling in metabolic syndrome, type 2 diabetes mellitus, and diabetic nephropathy: Paying homage to the podocyte. Am J Nephrol 25 (2005) 553-569
50. Blendea M.C., Jacobs D., Stump C.S., et al. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab 288 (2005) E353-E359
51. [published corrections appear in JAMA. 2003;289:178 and JAMA. 2004;291:2196]. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group and the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 (2002) 2981-2997
52. Bakris G.L., Fonseca V., Katholi R.E., et al., GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hyperten sion: A randomized controlled trial. JAMA 292 (2004) 2227-2236
53. Bell D.S. Optimizing treatment of diabetes and cardiovascular disease with combined alpha, beta-blockade. Curr Med Res Opin 21 (2005) 1191-1200
54. Bakris G.L., and Sowers J.R. When does new onset diabetes resulting from antihypertensive therapy increase cardiovascular risk. Hypertension 43 (2004) 941-942
55. Bakris G.L., Weir M.R., and Sowers J.R. Therapeutic challenges in the obese diabetic patient with hypertension. Am J Med 101 (1996) 335-465
56. Weinberger M.H., White W.B., Ruilope L.M., et al. Effects of eplerenone versus losartan in patients with low-renin hypertension. Am Heart J 150 (2005) 426-433
57. Gradman A.H., Schmieder R.E., Lins R.L., et al. Aliskiren, a novel orally effective renin inhibitor, provides dosedependent antihypertensive efficacy and placebo-like tol erability in hypertensive patients. Circulation 111 (2005) 1012-1018
58. Hsueh W.A., and Law R.E. PPARgamma and atherosclerosis: Effects on cell growth and movement. Arterioscler Thromb Vasc Biol 21 (2001) 1891-1895
59. Plutzky J. Peroxisome proliferator-activated receptors in vascular biology and atherosclerosis: Emerging insights for evolving paradigms. Curr Atheroscler Rep 2 (2000) 327-335
60. Negro R., Mangieri T., Dazzi D., et al. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Diabetes Res Clin Pract 70 (2005) 20-25
61. Ryan M.L., Didion S.P., Mathur S., et al. PPAR (gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 43 (2004) 661-666
62. Buchanan T.A., Meehan W.P., Jeng Y.Y., et al. Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect. J Clin Invest 96 (1995) 354-360
63. Tenenbaum A., Motto M., and Fisman E.Z. Dual and panperoxisome proliferator-activated receptors (PPAR) coagonism: The bezafibrate lessons. Cardiovasc Diabetol 4 (2005) 14
64. Lucluet S., Gaudel C., Hoist D., et al. Roles of PPAR delta in lipid absorption and metabolism: A new target for the treatment of type 2 diabetes. Biochim Biophys Acta 1740 (2005) 313-317
65. Keane W.E., and Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation. Am J Kidney Dis 33 (1999) 1004-1010
66. American Diabetes Association. Clinical practice recommendations 2001. Diabetes Care 24 Suppl 1 (2001) S69-S72
67. Varghese A., Deepa R., Rema M., and Mohan V. Prevalence of microalbuminuria in type 2 diabetes mellitus at a diabetes centre in southern India. Postgrad Med J 77 (2001) 399-402
68. Young B.A., Katon W.J., Von Korff M., et al. Racial and ethnic differences in microalbuminuria prevalence in a diabetes population: The pathways study. J Am Soc Nephrol 16 (2005) 219-228
69. Kraft S.K., Lazaridis E.N., Qu C., et al. Screening and treatment of diabetic nephropathy by primary care physicians. J Gen Intern Med 14 (1999) 88-97
70. Available at:. Champion P.K., Kuo G.M., Greisinger A., and Steinbauer J.R. Microalbumin testing in patients with type-2 diabetes: A SPUR-Net study. Accessed (September 25, 2005). http://www.spurnetwork.org/projects/microalbumin.html
71. McFarlane S.I., Jacober S.L., Winer N., et al. Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 25 (2002) 718-723
72. Hayden M.R., and Tyagi S.C. Isolated low high density lipoprotein-cholesterol (HDL-C): Implications of global risk reduction. Case report and systemic scientific review. Cardiovasc Diabetol 4 (2005) 1
73. Gaede P., and Pedersen O. Multi-targeted and aggressive treatment of patients with type 2 diabetes at high risk: What are we waiting for?. Horm Metab Res 37 Suppl 1 (2005) 76-82
74. Burke L.E., Dunbar-Jacob J.M., and Hill M.N. Compliance with cardiovascular disease prevention strategies: A review of the research. Ann Behav Med 19 (1997) 239-263
75. San Francisco, Calif. Giles T.D. The new definition of hypertension. Latebreaking clinical trials. Program and abstracts of the 20th Annual Scientific Meeting of the American Society of Hypertension (May 14-18, 2005)
76. DeFronzo R.A. Lilly lecture 1987. The triumvirate: Betacell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37 (1988) 667-687
77. Reaven G.M. The fourth musketeer-from Alexandre Dumas to Claude Bernard. Diabetologia 38 (1995) 3-13
78. Giacchetti G., Sechi L.A., Rilli S., and Carey R.M. The reninangiotensin-aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 16 (2005) 120-126
79. Grundy S.M., Cleeman J.I., Daniels S.R., et al., American Heart Association and the National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112 (2005) 2735-2752